SCHEMBL10316004

SCHEMBL10316004

c1ccc(N2CCC(C3CCNCC3)CC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.64
HTR3E A5X5Y0 1/20 0.64
HTR3B O95264 1/20 0.64
ADRB1 P08588 1/20 0.64
HTR3A P46098 1/20 0.64
HTR3D Q70Z44 1/20 0.64
HTR3C Q8WXA8 1/20 0.64
USP2 O75604 3/20 0.53
CYP2D6 P10635 2/20 0.53
SLC18A3 Q16572 2/20 0.50
MBTD1 Q05BQ5 1/20 0.50
L3MBTL3 Q96JM7 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
BPTF Q12830 1/20 0.48
GPR119 Q8TDV5 1/20 0.48
HTR1A P08908 1/20 0.47
HTR7 P34969 1/20 0.47
LTA4H P09960 1/20 0.47
TSHR P16473 3/20 0.46
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10316005 0.88 MBTD1 (0.61) SIGMAR1HTR3EHTR3BADRB1HTR3A
SCHEMBL4434108 0.81 LTA4H (0.56) SIGMAR1HTR3EHTR3BADRB1HTR3A
SCHEMBL29471969 0.81 PIM1 (0.43) SIGMAR1HTR3EHTR3BADRB1HTR3A
SCHEMBL4761698 0.81 ADRB2 (0.67) SIGMAR1HTR3EHTR3BADRB1HTR3A
SCHEMBL10315999 0.80 L3MBTL3 (0.58) SIGMAR1HTR3EHTR3BADRB1HTR3A
SCHEMBL14138620 0.80 ADRB1 (0.71) SIGMAR1HTR3EHTR3BADRB1HTR3A
Phenylpiperazine SCHEMBL55125 0.79 ADRB1 (1.00) SIGMAR1HTR3EHTR3BADRB1HTR3A
Phenylpiperazine SCHEMBL24889 0.79 ADRB1 (1.00) SIGMAR1HTR3EHTR3BADRB1HTR3A
Phenylpiperazine SCHEMBL29135595 0.79 ADRB1 (1.00) SIGMAR1HTR3EHTR3BADRB1HTR3A
Phenylpiperazine SCHEMBL27858598 0.79 ADRB1 (1.00) SIGMAR1HTR3EHTR3BADRB1HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217978-A1 COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2024-07-04 US disclosed
US-8445499-B2 Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment MERCK SHARP & DOHME CORP. (US) 2013-05-21 US disclosed
US-8399485-B2 Acyl bipiperidinyl compounds useful as GPR 119 agonists MERCK SHARP & DOHME CORP. (US) 2013-03-19 US disclosed
US-20120178681-A1 BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-20100075987-A1 ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME CORP. 2010-03-25 US disclosed
US-20100029688-A1 BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME CORP. 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075987-A1 ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT GPR119, GPR27, FFAR2 SIGMAR1 1661/4885HTR3E 738/4885HTR3B 293/4885
US-20100029688-A1 BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT GPR119, GPR139, GPR27 SIGMAR1 1463/4885HTR3E 651/4885HTR3B 259/4885
US-20240217978-A1 COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ADORA2A, ADORA1, ADORA2B SIGMAR1 457/4885HTR3E 121/4885HTR3B 65/4885
US-20120178681-A1 BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT GPR119, GPR139, GPR27 SIGMAR1 1055/4885HTR3E 612/4885HTR3B 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.